First Manhattan’s BeOne Medicines Ltd ONC Stock Holding History

First Manhattan’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-51	Closed	-$11.2K	–	1725
2022 Q4	$11.2K	Buy	+51	New	+$9.35K	﹤0.01%	1231

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

First Manhattan's ONC Position: Q1 2023 in Review

First Manhattan sold out of BeOne Medicines Ltd (ONC) in Q1 2023, closing a stake of 51 shares — an estimated $11.2K sold.

First Manhattan first reported a position in ONC in Q4 2022 and held it in 1 quarter. The position peaked at $11.2K in Q4 2022. 220 funds tracked by Wall St. Rank hold ONC as of Q1 2023.

First Manhattan reported no remaining BeOne Medicines Ltd position as of Q1 2023 after selling out during the quarter.
First Manhattan sold 51 BeOne Medicines Ltd shares in Q1 2023, an estimated $11.2K.
First Manhattan first reported a position in BeOne Medicines Ltd in Q4 2022 and held it in 1 quarter.
First Manhattan's BeOne Medicines Ltd position peaked at $11.2K in Q4 2022.
220 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2023.

Based on First Manhattan's 13F filing for Q1 2023, filed 15 May 2023.